Parcom Capital has acquired Viroclinics Biosciences, a CRO based in The Netherlands that specializes in testing new vaccines and drugs in the clinical trial stages prior to market launch. Viroclinics employs more than 100 people and works with clients around the world.

Viroclinics tests around 90% of all anti-influenza medications developed worldwide. The company expects to see further growth in other fields of virology in the coming years.
 
Bob van Gemen, chief executive officer of Viroclinics Biosciences said, “Our main focus at the moment is the research and treatment of respiratory viruses. We would like to broaden our portfolio, especially in the area of other viral targets, such as hepatitis, polio and RSV. For instance, we are very closely involved in a project that is on the verge of eradicating the polio virus for good. In Parcom Capital, we have found a new, solid partner who will enable us to realise even more of our ambitious targets. In the coming years, we will enter a new phase as a company and we have major growth ambitions.”
 
Viroclinics is now fully owned by Parcom Capital. Parcom has made several investments in Dutch companies in recent years, including the mobile telecom provider Simpel.nl, Star Group and RH Marine. “We see Viroclinics as a valuable addition to our portfolio,” said Parcom Capital partner Piet-Hein de Jager. “We believe very strongly in the growth opportunities for Viroclinics, which has acquired a leading position in the biopharma market with its expertise and innovative approach.”